X4 PHARMACEUTICALS INC (XFOR) Stock Price, Quote, News and Overview
NASDAQ:XFOR - Nasdaq - US98420X1037 - Common Stock - Currency: USD
XFOR Quote, Performance and Key Statistics
4.35
-0.99 (-18.46%)
The current stock price of XFOR is 4.35 USD. In the past month the price decreased by -38.66%. In the past year, price decreased by -87.39%.
XFOR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.84 | 342.32B | ||
| AMGN | AMGEN INC | 14.56 | 155.14B | ||
| GILD | GILEAD SCIENCES INC | 13.46 | 129.91B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1736.21 | 129.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.47 | 62.19B | ||
| ARGX | ARGENX SE - ADR | 331.32 | 38.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.46B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.92B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| BIIB | BIOGEN INC | 7.3 | 17.59B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.42B |
Related stock screener links
About XFOR
Company Profile
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
X4 PHARMACEUTICALS INC
61 North Beacon Street, 4th Floor
Boston MASSACHUSETTS 02134 US
CEO: Paula Ragan
Employees: 127
Company Website: https://www.x4pharma.com/
Investor Relations: https://investors.x4pharma.com/
Phone: 18575298300
X4 PHARMACEUTICALS INC / XFOR FAQ
What is the stock price of X4 PHARMACEUTICALS INC today?
The current stock price of XFOR is 4.35 USD. The price decreased by -18.46% in the last trading session.
What is the ticker symbol for X4 PHARMACEUTICALS INC stock?
The exchange symbol of X4 PHARMACEUTICALS INC is XFOR and it is listed on the Nasdaq exchange.
On which exchange is XFOR stock listed?
XFOR stock is listed on the Nasdaq exchange.
What is X4 PHARMACEUTICALS INC worth?
X4 PHARMACEUTICALS INC (XFOR) has a market capitalization of 755.42M USD. This makes XFOR a Small Cap stock.
How many employees does X4 PHARMACEUTICALS INC have?
X4 PHARMACEUTICALS INC (XFOR) currently has 127 employees.
Is X4 PHARMACEUTICALS INC (XFOR) expected to grow?
The Revenue of X4 PHARMACEUTICALS INC (XFOR) is expected to grow by 421.81% in the next year. Check the estimates tab for more information on the XFOR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy X4 PHARMACEUTICALS INC (XFOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XFOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XFOR, evaluating the profitability, health, valuation and growth aspects
- X4 PHARMACEUTICALS INC (XFOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- X4 PHARMACEUTICALS INC (XFOR) Sales and EPS estimates to see what analysts future expectations are.
- X4 PHARMACEUTICALS INC (XFOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- X4 PHARMACEUTICALS INC (XFOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- X4 PHARMACEUTICALS INC (XFOR) Stock Chart to make your own analysis
- X4 PHARMACEUTICALS INC (XFOR) Latest news and press-releases to stay up to date.
Does X4 PHARMACEUTICALS INC (XFOR) stock pay dividends?
XFOR does not pay a dividend.
When does X4 PHARMACEUTICALS INC (XFOR) report earnings?
X4 PHARMACEUTICALS INC (XFOR) will report earnings on 2025-05-01, before the market open.
What is the Price/Earnings (PE) ratio of X4 PHARMACEUTICALS INC (XFOR)?
X4 PHARMACEUTICALS INC (XFOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.71).
XFOR Technical Analysis
XFOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XFOR. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative.
XFOR Financial Highlights
Over the last trailing twelve months XFOR reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -18.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.57% | ||
| ROE | -169.08% | ||
| Debt/Equity | 3.41 |
XFOR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to XFOR. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 24.72% and a revenue growth 421.81% for XFOR